Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

BALA CYNWYD, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

AVROBIO, Inc. (Nasdaq – AVRO)

Under the terms of the agreement, AVROBIO will merge with Tectonic Therapeutic, Inc. (“Tectonic”). In the deal, pre-Merger AVROBIO shareholders are expected to own approximately 22.3% of the combined company and pre-Merger Tectonic shareholders are expected to own approximately 40.2% of the combined company. Following the closing of the Merger, the combined company will be led by the Tectonic management team. AVROBIO will be renamed Tectonic Therapeutic, Inc. The investigation concerns whether the AVROBIO Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to AVROBIO shareholders in the combined company.

Additional information can be found at https://www.brodskysmith.com/cases/avrobio-inc-nasdaq-avro/.

California BanCorp (Nasdaq – CALB)

Under the terms of the agreement, California Bancorp will merge with Southern California Bancorp (Nasdaq - BCAL). The companies will combine in an all-stock merger valued at approximately $233.6 million, or $26.54 per share of California BanCorp, based on the closing price of Southern California Bancorp on January 29, 2024. Specifically, each outstanding share of California BanCorp common stock will be exchanged for the right to receive 1.590 shares of Southern California Bancorp common stock. As a result of the transaction, Southern California Bancorp shareholders will own approximately 57.1% of the outstanding shares of the combined company and California BanCorp shareholders will own approximately 42.9% of the outstanding shares of the combined company. The investigation concerns whether the California BanCorp Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to California BanCorp shareholders in the combined company.

Additional information can be found at https://www.brodskysmith.com/cases/california-bancorp-nasdaq-calb/.

Karuna Therapeutics, Inc. (Nasdaq – KRTX)

Under the terms of the Merger Agreement, Karuna Therapeutics will be acquired by Bristol Myers Squibb (NYSE: BMY) in an all-cash transaction valued at approximately $14 billion. Karuna Therapeutics stockholders will receive $330.00 per share in cash upon completion of the proposed transaction. The investigation concerns whether the Karuna Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Bristol Myers Squibb is paying fair value to shareholders of the Company.

Additional information can be found at https://www.brodskysmith.com/cases/karuna-therapeutics-inc-nasdaq-krtx/.

Exro Technologies Inc. (OTC - EXROF)

Under the terms of the agreement, Exro Technologies will merge with SEA Electric Inc. (“SEA Electric”). Immediately following the closing of the Transaction, Exro shareholders will own an approximate 34.5% economic stake in the combined company and SEA Electric shareholders will own an approximate 65.5% economic stake in the combined company. The investigation concerns whether the Exro Technologies Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to Exro Technologies shareholders in the combined company.

Additional information can be found at https://www.brodskysmith.com/cases/exro-technologies-inc-otc-exrof/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.